Pfizer cuts sales forecast after Zoetis spinoff; Valeant's bond issue faces tough market; Roche settles Xeloda patent fight;

@FiercePharma: Eisai pulls seizure drug Fycompa in Germany to protest "appalling" pricing decision. Article | Follow @FiercePharma

@EricPFierce: Impax CEO Larry Hsu, whose company has been sidetracked by FDA manufacturing issues, is retiring. Story | Follow @EricPFierce

@CarlyHFierce: GSK CEO Andrew Witty's M&A aim: Sell more, buy less. Story | Follow @CarlyHFierce

> Pfizer ($PFE) updated its 2013 forecast to account for the full-and-final spinoff of its animal health business, Zoetis; the company now expects sales to come in at $50.8 billion to $52.8 billion, down from $55.3 billion to $57.3 bilion; earnings are pegged at $2.10 to $2.20, rather than $2.14 to $2.24. Report

> Valeant Pharmaceuticals ($VRX) has hit a snag on its bond issue to raise money for its Bausch + Lomb acquisition; the company will likely have to allow a higher yield than it initially expected. Report

> Roche settled a patent dispute with India's Intas Pharmaceuticals, allowing the generic drugmaker to sell its version of the cancer treatment Xeloda in the U.S. before the drug loses exclusivity. Report

> Britain's National Institute of Health and Care Excellence told doctors to offer breast cancer drugs tamoxifen or raloxifene to high-risk women over 35. Report

> Pfizer lost its Supreme Court bid for a shield from asbestos lawsuits connected to its Quigley Co. subsidiary, which made products containing the substance until the 1970s. Report

> Actavis ($ACT) won Canadian approval to market Fibristal, its new treatment for uterine fibroid symptoms. Release

> India's Strides Arcolab said its combination malaria drug won World Health Organization pre-qualification. Report

Medical Device News

@FierceMedDev: Acutus hauls in $21M for a-fib imaging. Article | Follow @FierceMedDev

@DamianFierce: Not to be outdone by J&J, Medtronic is starting an artificial pancreas study of its own. News | Follow @DamianFierce

@MichaelGFierce: EnteroMedics files with FDA despite obesity-device trial flop. News | Follow @MichaelGFierce

> CardioFocus kicks off EU atrial fibrillation trial. Item

> Study: Boston Scientific's S-ICD safer than standard implants. More

Biotech News

@FierceBiotech: Astellas bites off $490M deal to develop muscle drugs with Cytokinetics. News | Follow @FierceBiotech

 @JohnCFierce: Bayer beefs up cancer drug pipeline with $520M armed antibody deal with Seattle Genetics. Story | Follow @JohnCFierce

@RyanMFierce: Where were the breakthrough drugs for diabetes at 2013 ADA? Report | Follow @RyanMFierce

> Isis steals diabetes drug spotlight with new approach to slashing blood fat. More

> Glaxo's diabetes drug fails to beat Takeda's Actos in head-to-head study. Report

Biotech Research News

 @EmilyMFierce: Lack of gene could predict earlier onset, severity of multiple sclerosis. Article | Follow @EmilyMFierce

> RNA molecule could reduce fat in bloodstream, regulate high cholesterol. More

> New target could be key to preventing epilepsy. Article

> Virus combo kills brain tumor cells in preclinical model. Story

> Penn scientists create human-cell model of pancreatic cancer. Article

> Antioxidant improves motor functions in mice with Parkinson's. Item

Pharma Manufacturing News

> India court quashes lawsuit against Ranbaxy plants. Item

> Pfizer quells fears of cuts at Ireland plant that makes Viagra. More

> Impax to get new CEO as it tries to right manufacturing issues. Article

> U.S. gets EU waiver on APIs in the nick of time. Story

And Finally... Need a surge of creativity? Listen to the sounds of a coffee shop. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.